Hanmi Pharmaceutical's obesity treatment technology export and JPMorgan's upgrade of Samsung SDI's investment opinion drove the market.
Want the next one from this channel too?
Hanmi Pharmaceutical recorded its upper limit today after news of a technology export transfer exceeding ₩260 billion. This contract is for the HM17321 platform technology, with a specific contract value of ₩262.9 billion. The contract was signed with Genentech, a subsidiary of the Swiss pharmaceutical company Roche.
The HM17321 substance focuses on solving muscle loss, one of the main side effects of existing obesity treatments. This technology's core function is to prevent muscle loss, and it is expected to enhance the sustainability of treatment effects through the application of long-acting platform technology.
Through this technology export contract, Hanmi Pharmaceutical will receive milestone bonuses at each clinical stage. These are success-based payments, disbursed as each development stage successfully progresses. Additionally, royalty revenues from the global rights transfer are expected to generate further income separate from the milestone bonuses.
Hanmi Pharmaceutical's upper limit is a natural outcome, and the upward trend is likely to continue until the end of this week. Investors are recommended to hold their shares until the end of this week. News of Hanmi Pharmaceutical's technology export is expected to positively impact the entire bio sector, potentially leading to a concurrent rise in other biotech stocks.
This morning, positive comments from JPMorgan on Samsung SDI led to an overall strength in secondary battery stocks. JPMorgan issued an 'overweight' opinion on Samsung SDI, suggesting that more shares could be purchased. The sustained rise in lithium carbonate prices also positively impacted the secondary battery sector. Additionally, issues related to battery shortages for data centers are also interpreted as contributing to the stock price increase of secondary battery-related companies.
The sharp rise in the secondary battery sector is also attributable to technical factors. Rebound buying flowed into stocks that had previously experienced excessive declines. In particular, as supply and demand normalized, short covering, or repurchases by short-selling forces, fueled the stock price increase. Analysts suggest that the strong buying pressure during the process of major short sellers buying back shares led to the sharp rise.
Answers come from the transcript, with the exact spot cited.
Want the next one from this channel too?
When MBN골드 publishes, we'll write it up like the one you just read and email it to you.
{channel} published 95 in the last 7 days.
We skip Shorts. You can unfollow any time.
